FILE PHOTO: A logo is pictured on the Ibex building of Lonza, where the Moderna mRNA coronavirus disease (COVID-19) vaccine will be produced, in Visp, Switzerland, September 29, 2020.

Lonza shares rise 6.7% after CHI exit announcement Company to focus on CDMO business restructuring Plans M&A for tech and capacity opportunities Dec 12 (Reuters) - Swiss contract drugmaker Lonza ...